S
Sapience Therapeutics
A preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs
About Sapience Therapeutics
Sapience Therapeutics is a biotechnology company focused on developing peptide inhibitors to target intracellular protein-protein interactions in cancer cells. The company's discovery platform generates drug candidates that specifically address transcriptional regulation of oncogenic and immune modulatory proteins. Their lead candidate, ST101, is designed to induce cell death in solid tumors such as breast cancer, melanoma, prostate cancer, and glioblastoma, as well as in hematologic malignancies. Sapience Therapeutics operates in the oncology market, serving patients with unmet medical needs. The company generates revenue through the development and potential commercialization of its therapeutic candidates.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Town of Greenburgh, United States
- Employees
- 25
- Open positions
- None listed
- Dealroom signal
- 62.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Neurology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | May 2023 | $2M | — | National Cancer Institute SBIR Development Center | ↗ |
| GRANTOther financing | Oct 2022 | — | — | National Cancer Institute SBIR Development Center | ↗ |
Growth signals
Latest recorded traffic for Sapience Therapeutics is 2.9K monthly website visits, up 52.6% over the last three months. Sapience Therapeutics's team declined 21.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Sapience Therapeutics in the Town of Greenburgh ecosystem
The Sapience Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Small Business Innovation Research
US National Institute of Allergy and Infectious Diseases
National Cancer Institute SBIR Development Center
Series A8 investors entered at this stage
Eshelman Ventures
Celgene- HCHealthlink Capital
- TTTaiAn Technologies
Connectivity Ventures Fund
NexPoint
Bristol-Myers Squibb- KCKingdon Capital
Other known investors1 additional known investor
Columbia University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sapience Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sapience Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










